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A combination of LCPUFA ameliorates airway inflammation
in asthmatic mice by promoting pro-resolving effects and
reducing adverse effects of EPA
D. Fussbroich1,2,3, R. A. Colas4, O. Eickmeier2, J. Trischler2, S. P. Jerkic2, K. Zimmermann1, A. Göpel1, T. Schwenger1, A. Schaible5,
D. Henrich5, P. Baer6, S. Zielen2, J. Dalli4,7, C. Beermann1 and R. Schubert2
Lipid mediators derived from omega (n)-3 and n-6 long-chain polyunsaturated fatty acids (LCPUFA) play key roles in
bronchoconstriction, airway inflammation, and resolution processes in asthma. This study compared the effects of dietary
supplementation with either a combination of LCPUFAs or eicosapentaenoic acid (EPA) alone to investigate whether the
combination has superior beneficial effects on the outcome of asthmatic mice. Mice were sensitized with house dust mite (HDM)
extract, and subsequently supplemented with either a combination of LCPUFAs or EPA alone in a recall asthma model. After the
final HDM and LCPUFA administration, airway hyperresponsiveness (AHR), bronchoalveolar lavages, and lung histochemistry were
examined. Lipid mediator profiles were determined by liquid chromatography coupled with tandem mass spectrometry
(LC–MS–MS). The LCPUFA combination reduced AHR, eosinophilic inflammation, and inflammatory cytokines (IL-5, IFN-γ, and IL-6)
in asthmatic mice, whereas EPA enhanced inflammation. The combination of LCPUFAs was more potent in downregulating EPA-
derived LTB5 and LTC5 and in supporting DHA-derived RvD1 and RvD4 (2.22-fold and 2.58-fold higher levels) than EPA alone. Ex
vivo experiments showed that LTB5 contributes to granulocytes’ migration and M1-polarization in monocytes. Consequently, the
LCPUFA combination ameliorated airway inflammation by inhibiting adverse effects of EPA and promoting pro-resolving effects
supporting the lipid mediator-dependent resolution program.
Mucosal Immunology (2020) 13:481–492; https://doi.org/10.1038/s41385-019-0245-2
INTRODUCTION
Characterized by chronic respiratory eosinophilic inflammation,
airway hyperresponsiveness (AHR), and remodeling of airways,
asthma is a chronic disease affecting 300 million people
worldwide.1,2 In recent years, lipid mediators have been shown
to play an essential role in inflammatory processes in asthma.3,4
Pro-inflammatory lipid mediators, such as prostaglandins, leuko-
trienes, and thromboxanes induce bronchoconstriction and
leukocyte infiltration, whereas specialized pro-resolving mediators
(SPMs) downregulate infiltration, cytokine, and chemokine pro-
duction and induce catabasis.3,5,6 Lipid mediators derive from
omega (n-)3 and n-6 long-chain polyunsaturated fatty acids
(LCPUFA), such as eicosapentaenoic (EPA), docosapentaenoic (n-3
DPA), docosahexaenoic (DHA), and arachidonic acid (AA). The pro-
inflammatory mediators derive mainly from AA and EPA, while
SPMs, such as E- and D-series resolvins, are biosynthesized from
EPA, n-3 DPA, and DHA. Thus, several pro-resolving effects (e.g.,
the decrease of AHR and airway eosinophilia) are described for
SPMs, such as RvE1, RvD1, PD1, LXA4 in asthma.
7–10
As therapeutic accompaniments in asthma, n-3 LCPUFAs, such as
fish oil-derivatives EPA or DHA, are suggested to be supplemented.11
However, there has been a lot of controversial data in recent years
about the efficacy of EPA and DHA supplementations in chronic
inflammation.12,13 One reason for the controversy may be that
combinations of EPA and DHA have superior effects on the outcome
of chronic inflammation compared with single-compound adminis-
trations.14 Consequently, we composed a LCPUFA blend and
compared it with EPA supplementation alone. To prove whether
the LCPUFA blend has significantly superior effects on allergic
asthma, we supplemented asthmatic mice with either LCPUFA
combination or EPA alone for 24 days. In contrast to EPA alone,
which had adverse effects on the clinical outcome, the LCPUFA
combination ameliorated the asthmatic situation significantly.
To understand why both supplementation strategies led to
different results even though both contained the same amount of
EPA, we determined lipid mediator profiles by liquid chromato-
graphy coupled with tandem mass spectrometry (LC–MS–MS)
after supplementation was given. The results showed distinctive
lipid mediator profiles for both supplementation strategies, which
suggest that the combination of LCPUFA impacts lipid mediator
biosynthesis and therefore, clinical outcome varies when different
supplementations are given.
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A combination of LCPUFAs but not EPA alone ameliorates airway
hyperresponsiveness in mice sensitized to house dust mite
After mice were sensitized with HDM or PBS as a control for 10
consecutive days, they either received no supplementation, a
combination of LCPUFAs, or single EPA supplementation for
24 days (Fig. 1a). For the last 3 days of supplementation (d32–d34),
mice received repetitive doses of HDM or PBS as a control. On day
35, they were then tracheotomized for lung function, and
bronchoalveolar lavage (BAL) measurements followed by tissue
collection.
The respiratory resistance (Rrs) reflecting AHR was measured
with increasing doses of methacholine (MCh) in a range of 1–100
mg/mL (Fig. 1b). AHR was reduced significantly in asthmatic mice
fed with the LCPUFA combination. At 50 and 100mg/mL MCh,
AHR was significantly lower in LCPUFA-supplemented asthmatic
mice compared with non-supplemented mice (50 mg/mL: HDM:
3.97 ± 0.57 cmH2O × s/mL; LCPUFA: 2.63 ± 0.22 cmH2O × s/mL (p <
0.05); 100mg/mL: HDM: 5.93 ± 1.01 cmH2O × s/mL; LCPUFA:
4.04 ± 0.47 cmH2O × s/mL (p < 0.001)). The LCPUFA combination
lowered AHR, while EPA supplementation alone did not decrease
AHR in asthmatic mice. Moreover, the respiratory resistance was
even increased at 50 mg/mL compared with non-supplemented
asthmatic mice (HDM: 3.97 ± 0.57 cmH2O × s/mL; EPA: 5.45 ±
1.22 cmH2O × s/mL (p < 0.05)).
sc-LCPUFA-supplemented asthmatic mice showed reduced airway
inflammation in contrast to EPA-supplemented asthmatic mice
Immune cells were counted and differentiated in BAL fluids of
control, non-supplemented asthmatic, LCPUFA- and EPA-
supplemented asthmatic mice. Compared with healthy mice,
sensitization with HDM led to a highly significant increase in total
immune cell numbers of asthmatic mice (PBS: 0.18 ± 0.05 × 106
cells/mL; HDM: 1.34 ± 0.16 × 106 cells/mL, p < 0.001) with eosino-
phils from 0.00 ± 0.00% to 57.45 ± 1.84% (p < 0.001). Thus,
confirming a significant induction of allergic asthma. Whereas
LCPUFA supplementation did not change the total cell count, EPA
supplementation increased the total cell counts in BALs of
asthmatic mice significantly (Fig. 1c: HDM: 1.34 ± 0.16 × 106 cells/
mL; LCPUFA: 1.10 ± 0.25 × 106 cells/mL; EPA: 2.37 ± 0.55 × 106
cells/mL, p < 0.01). Indeed, the total cell count was 2.15-fold
higher in BALs of EPA-supplemented mice compared with
LCPUFA-supplemented mice. Although the relative amount of
eosinophils was reduced significantly by both supplementation
strategies (Fig. 1c: eosinophils: PBS: 0.00 ± 0.00%, p < 0.001; HDM:
57.45 ± 1.84%; LCPUFA: 44.70 ± 1.45%, p < 0.001; EPA: 48.80 ±
2.35%, p < 0.01), EPA supplementation increased the total count of
macrophages in BALs of asthmatic mice significantly (Fig. 1c:
macrophages: PBS: 0.17 ± 0.05 × 106 cells/mL; HDM: 0.28 ± 0.05 ×
106 cells/mL; LCPUFA: 0.30 ± 0.08 × 106 cells/mL; EPA: 0.67 ±
0.19 × 106 cells/mL, p < 0.01).
To determine the impact of the dietary supplementation on TH1-
and TH2-responses, we measured IL-4, IL-5, IL-13, and IFN-γ in the
supernatants of BALs. Whereas the LCPUFA supplementation led to a
significant reduction in IL-5 and IFN-γ levels compared with non-
supplemented asthmatic mice, EPA-supplemented mice had sig-
nificantly higher IL-4, IL-5, and IFN-γ levels compared with LCPUFA-
supplemented asthmatic mice (Fig. 1d: IL-4: PBS: 0.00 ± 0.00 fg/mL,
p< 0.001; HDM: 13132.00 ± 2892.00 fg/ml; LCPUFA: 12458.00 ±
3410.00 fg/mL; EPA: 25154.00 ± 6255.00 fg/mL, p < 0.05; IL-5: PBS:
59.25 ± 16.0 fg/mL, p< 0.001; HDM: 13574.0 ± 3020.0 fg/mL; LCPUFA:
7181.00 ± 1142.00 fg/mL, p= 0.06; EPA: 20444.00 ± 6196.00 fg/mL;
IL-13: PBS: 0.00 ± 0.00 fg/mL; HDM: 1371.00 ± 934.50 fg/ml; LCPUFA:
0.00 ± 0.00 fg/mL; EPA: 4141.00 ± 2134.00 fg/mL; IFN-γ: PBS: 59.19 ±
2.29 fg/mL, p < 0.001; HDM: 2516.00 ± 653.10 fg/mL; LCPUFA:
548.90 ± 132.80 fg/mL, p < 0.05; EPA: 4934.00 ± 2043.00 fg/mL).
Furthermore, we examined IL-6 which was diminished significantly
by the LCPUFA combination, but almost significantly increased by
EPA supplementation compared with LCPUFA-supplemented mice
(Fig. 1d: IL-6: PBS: 93.25 ± 8.84 fg/mL, p < 0.001; HDM: 68791.00 ±
17601.00 fg/mL, LCPUFA: 27212.00 ± 7621.00 fg/mL, p < 0.05; EPA:
78843.00 ± 27842.00 fg/mL, p= 0.09). Of note, IL-10 levels, which
were increased in asthmatic mice compared with control mice, were
not significantly altered by LCPUFA or EPA supplementation (PBS:
493.40 ± 148.40 fg/mL; HDM: 1874.00 ± 345.80 fg/mL; LCPUFA:
1438.00 ± 270.5 fg/mL; EPA: 1589.00 ± 379.5 fg/mL).
Furthermore, H&E staining showed reduced eosinophilic
infiltration and septa swelling in LCPUFA-supplemented asthmatic
mice compared with non-supplemented asthmatic mice (Fig. 1e).
In contrast to the LCPUFA combination, EPA alone promoted cell
infiltration into the peribronchial regions of the lung compared
with non-supplemented asthmatic mice.
The release of EPA and n-3 DPA from cell membranes was
increased by both the LCPUFA combination and EPA alone
The total and free fatty acids were determined in lungs after MCh
challenge to examine (A) differences in incorporation of fatty
acids after LCPUFA and EPA supplementation and (B) free fatty
acid release upon MCh provocation in LCPUFA- and EPA-
supplemented asthmatic mice. The total amounts of EPA and
n-3 DPA were increased, and AA was reduced by both
supplementation strategies (Supplementary Table 1A). Differences
in the total fatty acid amount was found for DHA: The LCPUFA
combination increased DHA in lungs of asthmatic mice, whereas
EPA supplementation alone decreased DHA significantly. Upon
MCh challenge, both supplementation strategies led to a greater
release of EPA and n-3 DPA, whereas there was no significant
alteration of free DHA and AA in lungs of LCPUFA- and EPA-
supplemented asthmatic mice (Supplementary Table 1B).
Lipid mediator profiling in LCPUFA and EPA-supplemented
asthmatic mice
Given the role of specialized pro-resolving mediators and pro-
inflammatory eicosanoids, we determined the lipid mediator
profiles of non-supplemented, LCPUFA- and EPA-supplemented
asthmatic mice to identify the mechanisms of both supplemen-
tation strategies in order to explain the different clinical
outcomes. Therefore, lipid mediators were identified and
quantified by LC–MS–MS. Identification was conducted by
matching retention times (Fig. 2a) to authentic and synthetic
standards and to at least six diagnostic ions in the MS/MS spectra
(Fig. 2b). To visualize the distinct relations of the two
supplementation strategies to the lipid mediator biosynthesis, a
multivariate analysis was conducted. Partial least square projec-
tion to latent structures discriminant analysis (PLS-DA) score plot
(Fig. 2c) revealed that experimental groups form distinct clusters
due to the different supplementation strategies. Whereas SPMs
deriving from n-3 DPA and DHA were more abundant in mice fed
with the LCPUFA combination, EPA and AA-derived leukotrienes
were much more abundant in EPA-supplemented mice (loading
plot: Fig. 2d).
EPA- and n-3 DPA-derived SPMs were significantly elevated by
both the LCPUFA combination and EPA, however, D-series
resolvins (RvDs) were only maintained by the LCPUFA
combination
To differentiate individual changes in SPM production upon
supplementation, we analyzed EPA-, n-3 DPA-, and DHA-derived
SPMs (Supplementary Table 2; Fig. 3a–c). E-series resolvins (RvEs)
were increased in lungs by both LCPUFA (p= 0.05) and EPA
(p < 0.01) supplementation, although there were higher RvE2 levels
(p= 0.07) in EPA-supplemented asthmatic mice than in LCPUFA-
supplemented asthmatic mice (Fig. 3a). Though cumulative amounts
of n-3 DPA-derived resolvins (RvDsn-3 DPA) (Fig. 3b) were only
increased in LCPUFA- (p < 0.05) fed mice, which was consistent to a
significantly reduced amount of RvD1n-3DPA in EPA-supplemented
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mice (p < 0.05). In contrast to RvD1n-3 DPA, RvD5n-3 DPA was increased
by both supplementation strategies (LCPUFA: p < 0.05; EPA: p=
0.05). Thirteen-series resolvins (RvTs), including RvT3 and RvT4, were
elevated by both LCPUFA (p < 0.05) and EPA (p= 0.05) supplemen-
tation. While the cumulative amounts of SPMs deriving from DHA
(Fig. 3c) were not altered significantly, individual RvD1 and RvD4
quantities were diminished considerably by EPA supplementation. In
contrast, the concentrations of these mediators were maintained by
LCPUFA supplementation. Thus, RvD1 and RvD4 levels in lungs were
2.22-fold (p < 0.05) and 2.58-fold higher (p < 0.05) in LCPUFA-
supplemented asthmatic mice than in EPA-supplemented asthmatic
mice.
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Both LCPUFA and EPA supplementation decreased COX-2-
dependent AA-derived eicosanoids, but EPA-derived eicosanoids
were biosynthesized at greater levels in EPA-supplemented mice
Cyclooxygenase (COX)-2-dependent eicosanoids deriving from AA
or EPA (Fig. 4a–c) are known to impair the inflammatory response.
In our study, we observed that AA-derived mediators were
reduced significantly in asthmatic mice which were supplemented
with either LCPUFA (p < 0.05) or EPA (p < 0.05) compared with
non-supplemented mice. These changes were mainly due to
reductions in PGE2 and TxB2, which were diminished by both
supplementation strategies (Fig. 4b). Furthermore, PGD2 was
reduced in both sc-LCPUFA- (p= 0.1) and EPA-supplemented (p <
0.05) mice. In comparison, EPA-derived pro-inflammatory lipid
mediators (Fig. 4c) were increased highly significant by EPA (p <
0.01) and almost significant by the sc-LCPUFA blend (p= 0.05).
Thus, EPA-derived pro-inflammatory lipid mediators were 2.21-
fold greater in asthmatic mice fed with EPA than in asthmatic mice
being fed with LCPUFA. This was in accordance with the increased
concentrations of PGE3 and TxB3, which were increased by EPA
(both p < 0.01) more significantly than with the LCPUFA combina-
tion (p= 0.05; p < 0.05).
The LCPUFA combination induced reduced leukotriene
biosynthesis compared to EPA alone
Eicosanoids dependent on 5-lipoxygenase (LO) activity (Fig. 5a),
especially cysteinyl leukotrienes, such as LTC4 and LTC5, are
particularly interesting due to their bronchoconstrictive effects in
asthma. Whereas the cumulative levels of AA-derived leukotrienes
(LTs) were affected equally by LCPUFA combination and EPA alone
(Fig. 5b), there were significant differences for EPA-dependent
leukotrienes (Fig. 5c). Cumulative levels of EPA-derived LTs were
only increased by the EPA supplementation compared with non-
supplemented asthmatic mice (p < 0.05). Thus, they were 5.13-fold
higher after EPA supplementation alone compared with the
LCPUFA combination (p= 0.05). This difference was in line with
the significant increase of LTC5 (p < 0.01) and LTB5 (p < 0.01) in
EPA-supplemented asthmatic mice compared with non-
supplemented asthmatic mice. Thus, in asthmatic mice fed with
EPA alone, 9.47-fold higher levels of LTC5 (p < 0.05) and 3.03-fold
higher LTB5 levels (p= 0.11) were detected compared with the
LCPUFA combination.
To address the pro-inflammatory potency of EPA-derived
mediators, chemotaxis assays on granulocytes and macrophage
polarization assays were conducted. In Fig. 6a, the results of the
chemotactic activity of PGE2 in comparison with PGE3 and LTB4 in
comparison with LTB5 are depicted. PGE2 as well as PGE3 did not
promote granulocytes recruitment. In contrast, LTB4 (p < 0.05)
significantly increased granulocyte recruitment at 1000 nM,
whereas LTB5 increased migration only tendentiously. However,
no statistically significant differences in recruitment of
granulocytes between PGE2 and PGE3 as well as LTB4 and LTB5
were observed. We next tested the ability of PGE2 and PGE3 on
macrophage polarization. Regarding the impact of PGE2 and PGE3
on macrophage polarization, both of these mediators reduced
CD14 expression in macrophages schewed toward an M1
phenotype using GM-CSF, IFN-γ, and LPS. On the other hand,
PGE2 and PGE3 promoted CD14 in macrophages differentiated
toward an M2 phenotype using M-CSF and IL-4. These mediators
also reduced the expression of CD64 (M1-marker) in M1-
differentiated macrophages and upregulated CD163 (M2-marker)
in M2-schewed macrophages. These findings suggest that both
lipid mediators display anti-inflammatory actions in regulating
macrophage polarization (Fig. 6b; Supplementary. Fig. 3C). In
contrast, LTB4 and LTB5, equally increased CD14 in M1- and M2-
induced macrophages, increased M1-markers, such as CD64, in
M1-induced macrophages and reduced M2-markers, such as
CD163 (LTB5: p < 0.05), in M2-induced macrophages (Fig. 6c;
Supplementary. Fig. 3).
In summary, EPA supplementation led to significant lower RvD1
and RvD4 levels, whereas the LCPUFA combination maintained
these SPMs (Fig. 7). Furthermore, EPA-derived 5-LO products, such
as LTB5 and LTC5 were increased in EPA supplemented but not
LCPUFA-supplemented asthmatic mice underlining the adverse
effects of single EPA supplementation.
DISCUSSION
Dietary supplementations with long-chain polyunsaturated fatty
acids, predominantly fish oil-associated eicosapentaenoic (C20:5n-
3) and docosahexaenoic acids (C22:6n-3), are being suggested as a
supportive treatment strategy in chronic inflammatory diseases,
such as asthma.11,14,15 Given the role of LCPUFA-derived pro-
inflammatory eicosanoids and SPMs on AHR, leukocyte infiltration,
and resolution of inflammation,3,5,16 LCPUFA supplementation has
a significant impact on the clinical outcome of asthma. To
investigate whether a LCPUFA combination is superior to EPA
supplementation alone, lung function measurements, histological,
and BAL analyses were conducted in an allergic asthma mouse
model. Furthermore, pro-inflammatory eicosanoids and pro-
resolving mediators in the lungs of these mice were analyzed,
to determine mechanisms for lipid mediator biosynthesis in
response to each supplementation strategy.
The LCPUFA combination ameliorated AHR during MCh
challenge and improved eosinophilic cell infiltration in lung tissue.
In contrast, EPA increased cellular and cytokine-driven inflamma-
tion and impaired lung function. The cellular increase was mainly
due to macrophages, which were concordant with elevated IFN-γ
and IL-6 levels. Macrophages play an important role in maintaining
and resolving inflammation, especially in tissues.16,17 Following the
dichotomic subtype classification of macrophages in asthma into
Fig. 1 LCPUFA combination ameliorates airway inflammation in asthmatic mice. a Schematic design of experiments to investigate the
efficacy of a LCPUFA combination versus an EPA only supplement in allergic asthma. Mice were sensitized with house dust mite (HDM) extract
(or PBS as CTRL) for 10 consecutive days (d1–d10) to induce allergic asthma. Then, they either received no supplementation, a LCPUFA
combination or EPA supplementation perorally for 24 days (d11–d34) on a daily basis. On the last 3 days (d32–d34), repetitive doses of HDM or
PBS were administered to mice to boost the allergic sensitization (recall model 33). Twenty-four hours after the final HDM and LCPUFA
administration, lung function measurements under MCh challenge and bronchoalveolar lavages (BALs) were conducted, and lungs were
collected for H&E staining, fatty acid and lipid mediator profiling in five experimental sessions. b Airway resistance response following a dose-
dependent methacholine (MCh) challenge (1‒100mg/mL) in asthmatic mice (HDM) compared with control mice (CTRL) or asthmatic mice,
either supplemented with a combination of LCPUFA (HDM+ LCPUFA) or EPA (HDM+ EPA) alone. Airway measurements were obtained using
the flexiVent system (SCIREQ, Montreal, Canada). The results are expressed as mean ± SEM; n= 11‒15. Differences were considered statistically
significant at p-values < 0.05. *p < 0.05, **p < 0.01, ***p < 0.001 were tested by two-way ANOVA with Bonferroni post hoc analysis (showing
significances for each group compared with HDM). c Changes in the cytological constitution of BALs in healthy, asthmatic, and LCPUFA- or
EPA-supplemented asthmatic mice. The results are expressed as mean ± SEM; n= 10‒20. d Total IL-4, IL-5, IL-13, IFN-γ, IL-6, and IL-10 cytokine
levels in BALs of healthy, asthmatic, and LCPUFA- or EPA-supplemented asthmatic mice. The results are expressed as mean ± SEM; n= 10‒15.
Differences were considered statistically significant at p-values < 0.05. *p < 0.05, **p < 0.01, ***p < 0.001 were tested by one-way ANOVA (each
group compared with HDM) with Dunnett’s post hoc test and Student’s t test or the corresponding nonparametric testing. e H&E staining of
lung tissue sections of healthy (PBS), asthmatic (HDM), or LCPUFA-supplemented asthmatic mice (HDM+ LCPUFA or HDM+ EPA) with
magnification of ×50 and ×200. Data represent one out of n= 3‒5 mice per group.
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Fig. 2 Lipid mediator identification and analysis in asthmatic mice supplemented with either a LCPUFA combination or EPA alone. Lipid
mediators were identified according to (a) their retention times in the MRM chromatograms and their (b) MS/MS spectra with at least six
diagnostic ions representatively shown for RvD1. Peaks in MS/MS spectra are depicted as percentage of base peak. Identification and
quantification were performed by liquid chromatography coupled with tandem mass spectrometry (LC–MS–MS). Relations between the two
supplementation strategies and lipid mediators were visualized by creating (c) score and (d) loading plots by partial least square projection to
latent structures discriminant analysis (PLS-DA). Green= HDM; Blue=HDM+ LCPUFA; Red= HDM+ EPA; n= 3–5 mice per group. Variables
with the best discriminatory power (variable importance in projection (VIP) ≥ 1) are highlighted in gray in the score plot.
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pro-inflammatory M1 and anti-inflammatory M2 macrophages,17
our results suggest the macrophages to be pro-inflammatory M1
macrophages, as deduced from elevated IL-6 and IFN-γ and
unaltered IL-10 levels. Regarding the reduction of IL-5 and IL-13, it
is also discussable that lung type 2 innate lymphoid cells (ILC2s)
might have been involved. ILC2s were nicely shown to be activated
by leukotrienes, such as LTC4 and LTB4 and to be inhibited by
PGE2.
18,19 Thus, it is discussable that they might have contributed
to the worsening of the clinical outcome in EPA-supplemented
asthmatic mice. However, we focused on the increased macro-
phage infiltration upon EPA supplementation, because this was
one obvious finding associated with the deterioration of asthmatic
mice under EPA supplementation.
To get deeper insights into the mechanisms of lipid mediator
programs and to understand why the supplementation strategies
led to different clinical outcomes, we determined lipid mediator
Fig. 3 Concentrations of specialized pro-resolving mediators (SPMs) in lung tissue of asthmatic mice, which received no
supplementation, the LCPUFA combination or EPA alone. Cumulative and individual levels of (a) EPA-derived E-series resolvins (RvE),
such as RvE1 and RvE2, (b) n-3 DPA-derived D-series resolvins (RvDn-3 DPA), such as RvD1n-3 DPA and RvD5n-3 DPA, thirteen-series resolvins (RvT),
such as RvT3 and RvT4, and (c) DHA-derived D-series resolvins (RvD), such as RvD1 and RvD4. The results are presented as mean pg/100mg ±
SEM; n= 3‒5 mice per group. Differences were considered statistically significant at p-values < 0.05. *p < 0.05; **p < 0.01; and ***p < 0.001
tested by Kruskal–Wallis test (each group compared with HDM) with Dunn’s post hoc test and Mann–Whitney test (HDM+ LCPUFA vs. HDM+
EPA).
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profiles by LC–MS–MS. We found that both supplementation
strategies increased EPA- and n-3 DPA-dependent SPM levels,
which were in line with the free fatty acid levels. Haworth et al.
administered 100 ng/d RvE1 to asthmatic mice for three
consecutive days, and showed a significant reduction in AHR at
100mg/ mL MCh and a distinctive reduction of eosinophil and
macrophage infiltration.7 Although we measured significant
increases in E-series resolvins in EPA-supplemented asthmatic
mice, we could not observe an amelioration of AHR and
eosinophilic infiltration. One reason for this might be the fact
that we did not apply RvE1 itself, and that EPA supplementation
led not only to increased RvE levels but also to diminished levels
of total DHA, which is a precursor for SPMs, such as RvD1 and
RvD4. Compared with LCPUFA-supplemented asthmatic mice,
RvD1 and RvD4 levels were 2.22-fold and 2.58-fold lower in the
EPA group. In contrast to EPA alone, the LCPUFA combination
maintained RvD1 and RvD4 levels, which was probably due to the
adding of DHA to the LCPUFA blend. Titos et al. found that DHA
and RvD1 induce a phenotypic switch in macrophages from a pro-
inflammatory classical activation profile toward an alternative anti-
inflammatory M2-like state.20 Therefore, EPA alone might have
been less effective at inducing the macrophage phenotypic switch
compared with the LCPUFA supplementation. This is consistent
with Li et al.21 who demonstrated that n-3 LCPUFA intake is
inversely longitudinally associated with the incidence of asthma,
but DHA administration has a greater inverse association than
EPA. In addition, Rogerio et al.8 showed reduced lung resistance
under methacholine challenge with 10 ng of RvD1, which is one-
tenth of the amount of RvE1 Haworth et al.7 administered. These
results emphasize the efficacy and significant roles of DHA-derived
D-series resolvins in asthma. Notably, RvD1 has been shown
to counter-regulate COX-2 and the translocation of 5-LO, which
lead to diminishing pro-inflammatory mediators in chronic
inflammation.22,23
In view of COX-2- and 5-LO-derived pro-inflammatory lipid
mediators, EPA supplementation might have caused the dete-
rioration of the asthmatic situation due to EPA being an alternate
substrate for both enzymes. Whereas both LCPUFA and EPA
supplementations decreased AA-derived PGE2, TxB2, as well as
PGD2 on one hand, we observed that EPA supplementation led to
a significant increase in PGE3 and TxB3 on the other hand. In
ex vivo experiments, PGE3 had no significant impact on the
infiltration of granulocytes, whereas LTB5 did tendentiously
increase granulocyte migration (Fig. 6a). However, PGE3 similarly
displayed anti-inflammatory potencies to PGE2 in regulating
macrophage polarization (Fig. 6b). Thus, an increase of PGE3 is
not likely to explain a further infiltration of cells into the lungs of
EPA-supplemented mice. Furthermore, significantly higher
Fig. 4 COX-2 dependant lipid mediators in the lungs of LCPUFA- and EPA-supplemented asthmatic mice. a Both AA and EPA are substrates
for COX-2 and can be converted into prostaglandins (PG), such as PGE2 and PGE3 as well as into thromboxanes (Tx), such as TxB2 and TxB3.
Individual and cumulative amounts of eicosanoids derived from (b) AA and (c) EPA in lungs of non-, LCPUFA-, or EPA-supplemented asthmatic
mice. The results are expressed as mean pg/100mg ± SEM; n= 3‒5 mice per group. Differences were considered as statistically significant
when p-values < 0.05. *p < 0.05, **p < 0.01, ***p < 0.001 tested by Kruskal–Wallis test (each group compared with HDM) with Dunn’s post hoc
test and Mann–Whitney test (HDM+ LCPUFA vs. HDM+ EPA).
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proportions of EPA were converted to pro-inflammatory mediators
in EPA-supplemented asthmatic mice, suggesting that the LCPUFA
blend was more efficient in counter-regulating COX-2 than
EPA alone.
Similar to COX-2 products, the 5-LO products (LTC5 and LTB5)
were found at significantly higher levels in EPA-supplemented
mice than in non- and LCPUFA-supplemented asthmatic mice.
Particularly, LTC5 was increased significantly higher (9.47-fold
higher, p < 0.05) in EPA-supplemented mice than in the LCPUFA
group. In contrast to LTB5, which is according to literature only
~5–10% as active as LTB4,
24 the 5-series cysteinyl leukotrienes
LTC5, LTD5, and LTE5 are comparable with their AA-derived
congeners, such as LTC4, in evoking nonvascular smooth muscle
contraction.24–26 This would explain why we did not observe any
amelioration of AHR in asthmatic mice fed with EPA. Thien et al.,27
who incubated human eosinophils with either EPA or AA,
observed that total LTC generation was nearly twofold higher in
cells incubated with EPA than in cells incubated with AA. Thus,
their results suggest that EPA does not inhibit the biosynthesis of
cysteinyl leukotrienes but actually stimulates their biosynthesis at
lower doses than AA.27 Furthermore, Chapkin et al.28 found that n-
3 LCPUFAs are incorporated differentially into macrophage
phospholipid subclasses after dietary fish oil supplementation. In
addition, they found that macrophage peptidoleukotriene synth-
esis was also strongly influenced by the fish oil supplementation
resulting in a significantly higher LTC5/LTC4 ratio. With regards to
increased LTB5-levels in EPA-supplemented mice, our in vitro
experiments demonstrated that LTB4 significantly increased the
recruitment of granulocytes, and LTB5 tendentiously increased
migration of granulocytes (Fig. 6a). However, LTB5 was as potent
as LTB4 in promoting M1-polarization and diminishing M2-
polarization in monocytes (Fig. 6c). Thus, the increased levels of
LTB5 might have led to further M1-macrophage infiltration into
the lungs of EPA-supplemented asthmatic mice. Therefore,
increased LTC5- and LTB5-levels are likely to play a major role
due to which we observed a promotion of airway inflammation in
asthmatic mice fed with EPA, instead of any amelioration of AHR.
It is feasible that significantly lower levels of RvD1 and RvD4 in
EPA-supplemented mice have led to higher 5-LO translocations,
and subsequently these have led to an increased cysteinyl
leukotriene biosynthesis. In contrast, LCPUFA combinations might
feature significantly different effects than individual LCPUFAs,
such as EPA, due to competitive substrate inhibition of enzymes,
altered carnitine transport, and modifications of distinct enzymes
Fig. 5 Both AA and EPA can be converted by 5-LO to monohydroperoxy 5-HPETE and 5-HPEPE which are in turn converted to
leukotrienes. a Both AA and EPA can be converted by 5-LO over monohydroperoxy 5-HPETE and 5-HPEPE. They are biosynthesized to
leukotrienes (LT) A4 and LTA5, which are then either converted into cysteinyl leukotriene LTC4 and LTC5 by glutathione-S-transferase or into
LTB4 and LTB5 by hydrolases. In panels b and c, cumulative and individual amounts AA- and EPA-derived leukotrienes, such as LTC4, LTC5, LTB4,
and LTB5, found in lungs of non-, LCPUFA-, or EPA-supplemented asthmatic mice are shown. The results are expressed as mean pg/100mg ±
SEM; n= 3‒5 mice per group. Differences were considered statistically significant at p-values < 0.05. *p < 0.05, **p < 0.01, ***p < 0.001 tested by
Kruskal–Wallis test (each group compared with HDM) with Dunn’s post hoc test and Mann–Whitney test (HDM+ LCPUFA vs. HDM+ EPA).
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involved in fatty acid and lipid mediator biosynthesis.15,23,28–31
Thus, LCPUFA combinations might exhibit beneficial synergistic
effects, which positively influence clinical outcomes.15 Supplemen-
tation of a n-3 and n-6 LCPUFA combination in humans has
been shown to reduce bronchial inflammation after low-dose
allergen challenge.32 Schubert et al.32 found that serum eosino-
phils, eosinophilic cationic protein, and in vitro cysteinyl
leukotrienes were significantly reduced in asthmatic patients
supplemented with a combined LCPUFA blend. Thus, our data
support the hypothesis of synergistic n-3 and n-6 LCPUFA
combination effects,15 concerning the restoration of fatty acid
homeostasis in cellular membranes, modifying lipid mediator
biosynthesis pathways, and controlling inflammatory processes by
focusing on resolution of inflammation in the bronchoalveolar
system.
In summary, LCPUFA supplementation led to an amelioration of
AHR as well as a reduction of eosinophilic cell infiltration and
remodeling of airways. In contrast, EPA supplementation caused
further infiltration of pro-inflammatory cells (i.e., macrophages)
into the lung. The LCPUFA combination was more potent in
downregulating EPA-derived pro-inflammatory mediators, such as
LTB5 and LTC5, and in supporting SPM biosynthesis. Consequently,
we demonstrated that a LCPUFA combination is more effective in
limiting and resolving inflammation in allergic asthma than a
single EPA administration by promoting pro-resolving effects and
reducing EPA-derived pro-inflammatory effects. Thus, we recom-




Female C57BL/6 mice were purchased from Charles River
Laboratories (Wilmington, Delaware) at the age of 6–8 weeks
and maintained in stainless steel cages under sterile conditions
with an alternating 12 h light/dark cycle at the university hospital
in Frankfurt. Mice were fed with water and lab chow (Ssniff, Soest,
Germany) with 6% fat content (C 14:0: 0.01%; C 16:0: 0.68%; C 16:1:
0.04%; C 18:0: 0.22%; C 18:1: 1.44%; C 18:2: 3.21%; C 18:3: 0.37%; C
20:0: 0.03%; C 20:1: 0.01%) ad libitum. All animal procedures were
performed according to protocols approved by the German
Animal Subjects Committee (Gen.Nr.FK/1036).
Allergic asthma mouse model
Allergic asthma was induced by sensitization with 40 µg house
dust mite extract (HDM; Dermatophagoides pteronyssinus, Greer,
Fig. 6 Comparison of the pro-inflammatory potency of EPA- and AA-derived prostaglandins and leukotrienes on the migration of human
granulocytes and the polarization of human macrophages. a Chemo-attractive potency of PGE2 and PGE3, or LTB4 and LTB5 on granulocytes.
Migrated granulocytes upon either 1000 nM PGE2, PGE3, LTB4, or LTB5 are represented as mean (% of migrated cells relative to total number of
cells) ± SEM (n= 6 out of n= 2 experiments). Impact of 1000 nM (b) PGE2, and PGE3 or (c) LTB4 or LTB5 on macrophage polarization. Cell
surface marker expression of CD14, CD64 (M1), and CD163 (M2) are represented as fold changes (FC) ± SEM (n= 3 out of n= 3 experiments).
Differences were considered statistically significant at p-values < 0.05 tested by a one-way ANOVA with Dunnett’s post hoc analysis or by a
Friedman test with Dunn’s post hoc analysis.
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New York City, New York) or with PBS (phosphate-buffered saline,
pH= 7.4, Life Technologies, Darmstadt, Germany) as control given
on a daily basis for 10 consecutive days (Fig. 1a). To suppress the
swallowing reflex, mice were anesthetized with isoflurane (initial
dose: 5%, maintenance dose: 2.5%, Baxter, Unterschleißheim,
Germany). Subsequently, mice have received either 25 µL of PBS
or 25 µL of HDM (1.6 mg/mL in PBS) intranasally. After 21 days of
rest, mice were given repetitive doses of 40 µg HDM (or PBS as
control) for another 3 consecutive days (as described in the recall
model33). All mouse experiments were performed in five experi-
mental sessions, in which we measured lung function, collected
BAL fluids and lungs for further measurements, such as H&E
staining and lipid mediator measurements.
Dietary supplementation
Dietary supplements were applied orally to each mouse for
24 days starting on day 11 (Fig. 1a). EPA supplementation
contained 1000mg/kg/day EPA. The LCPUFA combination con-
tained 1000mg/kg EPA, 229.6 mg/kg DHA, 246.0 mg/kg GLA, and
200.9 mg/kg SDA. The LCPUFA combination or EPA were mixed
freshly on a daily basis and diluted in 0.5% (w:v) gum arabic
solution (gum arabic powder, Carl Roth, Karlsruhe, Germany;
sterile water) to a final volume of 200 µL per dose, which was
inevitable to assure emulsification and a defined application
volume. Emulsions were homogenized using an ultrasonic
homogenizer (Sonopuls, Bandelin, Berlin, Germany) and they
were applied immediately to the mice via a feeding needle
(canula, 0.70 × 30mm, LL, curved, Knopf C, Robert Helwig GmbH,
Berlin, Germany), which was connected to a 1 -mL syringe (Becton
Dickinson, Frankfurt/Main, Germany).
Lung function
Twenty-four hours after the final administration of HDM to the
asthma mice or PBS to the control mice, all mice were anesthetized
with Xylazine (10 mg/kg; Bayer Vital, Leverkusen, Germany) and
Ketanest® (100mg/kg; CuraMed GmbH, Karlsruhe, Germany).
Thereafter, they received another anesthesia with lidocaine
(Xylocaine Pumpspray, 10mg/spray burst, Astra Zeneca, Wedel,
Germany) and became tracheotomized. The trachea was cannu-
lated by insertion of a tubing adapter (18 G, BD, Franklin Lakes,
New Jersey), which was fixed by a suture. Immediately after this,
mice were attached to the tubing of the lung function measure-
ment device for ventilation. Lung function was measured with a
flexiVent FX system with an integrated FX1 module (Scireq,
Montreal, QC, Canada). For methacholine challenge, a small particle
aeroneb nebulizer (aeroneb ultrasonic nebulizer, Scireq, Montreal,
QC, Canada) was attached to the FX1 module leading to Y-tubing
for ventilation (volume: 10mL/kg and frequency: 2.5 Hz). The
ventilation reached 150 breaths/min. After a short ventilation
period (Mouse Default CMV), the script for dose–response studies
(Mouse IV Dose Response rel. B) was started, and deep inflation
(v7.0) was performed to enlarge the lungs up to a pressure of 27
cmH2O in order to build stable experiment conditions by restoring
airway patency and normalizing lung volume. Thereafter, single
frequency forced oscillation (SnapShot-150 v7.0) and broadband
forced oscillation (Quick Prime-3 v7.0) were performed automati-
cally by the software. Three consecutive SnapShot and Quick Prime
perturbations and one deep inflation perturbation were under-
taken prior to methacholine (MCh) challenge. Subsequently, 12
measurements of SnapShot and Quick Prime perturbations for
each MCh concentration were conducted with increasing concen-
trations of MCh (1; 3.125; 6.25; 12.5; 25; 50; and 100mg/mL; w:v in
PBS). Changes in respiratory resistance (Rrs) were calculated from
peak values of Snapshot measures after each dose.
Bronchoalveolar lavage (BAL)
Following lung function measurements, bronchoalveolar lavages
were conducted by insertion of a cannula (Braunüle, 21 G,
shortened to 2 cm, B. Braun, Melsungen, Germany) into the
trachea which was fixed by a suture. BAL fluids were taken by slow
injection and subsequent aspiration of 1 mL PBS-EDTA solution
(0.5 mM EDTA; (w:v); Merck, Darmstadt, Germany) with a 1 -mL
syringe. Three aliquots were collected and stored on ice until
further preparation.
Subsequently, aliquots were centrifuged, and the supernatants
were collected for cytometric bead array (CBA) measurement. Cell
pellets were pooled and incubated with ACK lysis buffer (Sigma-
Aldrich, Taufkirchen, München, Germany) for 3 min to lyse any
remaining erythrocytes. The lysis reaction was stopped with PBS,
and supernatants were discarded after centrifugation. Subse-
quently, pellets were diluted in PBS, pooled, and cells were
counted with the Trypanblue method. Sixty thousand cells were
placed in cytospin holders (Single Cell Funnels, Tharmac,
Waldsolms, Germany) and applied to microscope slides using
cytocentrifugation (450 rpm, 6 min.; Cytospin 3, Shandon, Thermo
Fischer Scientic, Dreieich, Germany). After at least 12 h of drying,
slides were stained using Pappenheim’s stain (Giemsa’s azur eosin
and May-Grünwald’s modified eosine methylene blue solution,
Merck, Darmstadt, Germany) and covered with Eukitt® (Sigma-
Aldrich, Taufkirchen, Germany). Differentiation of cells was
conducted by counting 400 cells per slide using a light
microscope (Leica, DME, Wetzlar, Germany).
H&E staining
After flushing with PBS to remove erythrocytes, lungs were
perfused via the trachea with 4% paraformaldehyde (w:v; in PBS)
Fig. 7 Main differences in lipid mediator profiles of HDM-induced
asthmatic mice supplemented with either the LCPUFA combina-
tion or EPA alone, suggesting mechanisms for different clinical
outcomes. Whereas RvD1 and RvD4 were biosynthesized at
significantly lower levels in EPA-supplemented mice, pro-
inflammatory eicosanoids, such as LTB5 and LTC5, were significantly
higher in EPA-supplemented mice.
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for a minimum of 10 min and then stored for 24 h in 4%
paraformaldehyde. Thereafter, lungs were transferred to embed-
ding cassettes (Histosette 1, Simport, Bernard-Pilon, Canada),
washed in water, and stored in 100% ethanol (Sigma-Aldrich,
Taufkirchen, Germany) until they were completely dehydrated.
Dehydrated lungs were embedded in paraffin using embedding
forms (Medite online, Burgdorf, Germany) and an embedding
station (Medax, Salt Lake City, Utah). After storing paraffin-
embedded lungs for at least 2 h at −30 °C, 10 -µm lung tissue
sections were sliced using a Cryotom (CM3050S, Leica, Wetzlar,
Germany). Lung sections were placed on a microscope slide
(Superfrost®, Sondheim v. d. Rhön, Germany), smoothed in a water
bath at 40 °C, and then dried for at least 30min at room
temperature (RT). Staining was performed using hematoxylin for
10min (ready to use, Applichem, Darmstadt, Germany) and eosin
G for 3 min (Carl Roth, Karlsruhe, Germany; acidified with glacial
acetic acid). Subsequently, slides were treated with increasing
ethanol concentrations and xylol (Fischer Scientific, Dreieich,
Germany) and then covered with Histofluid (Marienfeld, Lauda-
Königshofen, Germany). Eosinophil and macrophage infiltration
were evaluated using an Observer Z1 microscope with Axio-
CamMRm, (Zeiss, Jena, Germany) and AxioVisionRel 4.72 software.
Cytokine measurement
The concentrations of IL-5, IFN-γ, IL-6, and IL-10 were examined in
one aliquot of BAL supernatants using the BD™ CBA Mouse
Enhanced Sensitivity Flex Set System and BD™ CBA Mouse
Enhanced Sensitivity Master Buffer Kit (both BD Bioscience,
Franklin Lakes, New Jersey). Each BD™ CBA Flex Set contained
one bead population with a distinctive fluorescence intensity, as
well as the appropriate phycoerythrin (PE) detection reagent and
standard. Frozen supernatants were thawed at RT and centrifuged
at 10,000 rpm for 10 min at 2 °C. In total, 50 µL of Flex Set
Standards (0.274–200 pg/mL) or samples were incubated with 20
µL capture bead mixture in 96-well plates (filter plates, Millipore
MultiScreenHTS-BV 1.2 µm, Merck, Darmstadt, Germany) in the dark
at RT for 2 h. Then, 20 µL of detection reagent A was added and
incubated for 2 h. After incubation, filter plates were washed using
a vacuum manifold (Millipore MultiScreenHTS Vacuum Manifold,
Merck, Darmstadt, Germany), and 20 µL of detection reagent B
were added and incubated for 1 h. Following three washes and
the addition of 150 µL wash buffer, tests were performed using a
BD FACS Verse™ (BD Biosciences, Franklin Lakes, New Jersey) and
analyzed by FCAP Array v3 Software (BD Biosciences, Franklin
Lakes, New Jersey). IL-4 and IL-13 were examined in another
aliquot of the same supernatants of BAL fluids used for IL-5, IFN-γ,
IL-6, and IL-10 using LEGENDplexTM Mouse Kit including appro-
priate beads, detection antibodies, and standards (BioLEGEND,
San Diego, USA). In all, 25 µL of each standard or sample was
mixed 1:2 (v:v) with wash buffer in a 96-well plate, and then
transferred into a 96-well filter plate. Afterwards, 25 µL of capture
beads were added to each well. The plate was then sealed and
placed onto a shaker for 2 h. After incubation, each well of the
filter plate was washed with 200 µL wash buffer two times using a
vacuum manifold (Millipore MultiScreenHTS Vacuum Manifold,
Merck, Darmstadt, Germany). Then, 25 µL of detection antibodies
were added to each well, and plate was sealed and placed on a
plate shaker for another hour followed by the addition of 25 µL
SA-PE and another 30min of shaking. After washing two times,
150 µL wash buffer were added to resuspend the beads on the
plate shaker for 1 min. Measurements were performed using BD
FACS VerseTM, as described above.
Lipid mediator profiling
Lungs were collected immediately from killed mice, snapped
frozen in liquid nitrogen, and stored at −80 °C until further sample
processing. Tissue was quenched in ice-cold methanol containing
500 pg of each deuterated (d) internal standard (d8-5S-
hydroxyeicosatetraenoic acid, d4-LTB4, d5-LXA4, d4PGE2, and d5-
RvD2) using a plastic rod. Samples were centrifuged, and one
aliquot of the supernatant was used for solid-phase extraction
using ExtraHera (Biotage), as previously described.34 Identification
and quantification were performed using LC–MS–MS, (Sciex 5500
and 6500+, Warrington, UK) acquiring parent and characteristic
daughter ions via multiple reaction monitoring after either
negative or positive electrospray ionization. Lipid mediators were
identified according to their retention time and by at least six
diagnostic ions in the mass spectra as further described by Dalli
and Serhan.34 Partial least square projection to latent structures
discriminant analysis (PLS-DA) was performed using SIMCA
14.1 software (Umetrics, Umea, Sweden). Evaluation of loading
plots was performed as previously described,35 and variables with
best discriminatory power (variable importance in projection ≥ 1)
were highlighted in the Score plot.
Chemotaxis assay
Human granulocytes were obtained by ficoll separation and
erythrocyte lysis with 1× red blood cell lysis solution (Miltenyi
Biotec, Bergisch Gladbach, Germany). After washing twice with
PBS, cell viability and cell count were assessed by standard 0.5%
(w:v) trypan blue cell staining (Biochrom, Berlin, Germany). For
chemotaxis experiments, the wells of ChemoTx® Plates (NeuroP-
robe, Gaithersburg, USA; 96-well plates, with 5 -µm pore size, 5.7 -
mm filter in diameter, 300 -µL capacity) were filled with 300 µL of
chemotactic reagents dissolved in migration buffer (Hanks'
solution with 20 mM HEPES and 0.1% BSA at pH= 7.6 (all
purchased from Sigma-Aldrich, Taufkirchen, Germany)). Chemo-
tactic reagents PGE2, PGE3, LTB4, and LTB5 were all purchased from
Cayman Chemicals (Ann Arbor, USA), which were initially
dissolved in ethanol and then diluted with migration buffer to
1000 nM. Eosinophilic cells were diluted to 6 × 106 cells/mL in
migration buffer, and 50 µL of the cell suspension (300.000 cells)
were placed on top of the filters. After 2 h at 37 °C incubation time,
cells on the top of the filter were discarded, and cells in the
solutions of the lower chambers were counted for 60 s with a
rapid flow rate using the FACSVerse flow cytometer (BD
Biosciences, Heidelberg, Germany) and the FACSuite software
v1.0.6 (BD Biosciences, Heidelberg, Germany).
Statistics
Data are displayed as mean ± standard error of the mean (SEM),
and were evaluated using GraphPad Prism 5 and 7 (GraphPad
Software, La Jolla, CA). Comparisons between more than two
groups and repeated measures (MCh challenge, Fig. 1b) were
analyzed using a two-way ANOVA with Bonferroni post hoc
analysis. Comparisons between more than two groups without
repeated measures were performed by using one-way ANOVA
with Dunnett’s post hoc analysis against the disease group (HDM).
Comparisons between more than two groups with repeated
measures were performed by using Friedman’s test with Dunn’s
post hoc analysis against the control group. In addition, unpaired t
tests were conducted to find differences between HDM+ LCPUFA
and HDM+ EPA. In case of not normally distributed data or
samples sizes less than five, we used the corresponding
nonparametric testing. Differences were considered statistically
significant at p < 0.05.
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